{"id":"flucelvax-quadrivalent-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated influenza virus antigens from four seasonal flu strains (two A subtypes and two B lineages) grown in mammalian cell culture rather than eggs. It works by presenting these antigens to the immune system, triggering both humoral (antibody) and cellular immune responses that provide protection against infection with matching influenza strains.","oneSentence":"Flucelvax Quadrivalent is an inactivated influenza vaccine produced using cell culture technology that stimulates immune response against four strains of influenza virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:49.833Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults and children"}]},"trialDetails":[{"nctId":"NCT04304768","phase":"PHASE4","title":"Opioid, HIV and Immune System","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2020-11-18","conditions":"Immune Defect","enrollment":400},{"nctId":"NCT07215858","phase":"PHASE2","title":"BPL-1357 Against H1N1 Influenza Virus Challenge","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2026-04-01","conditions":"Influenza, Human","enrollment":129},{"nctId":"NCT04381689","phase":"PHASE3","title":"Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Il-Yang Pharm. Co., Ltd.","startDate":"2024-10-23","conditions":"Healthy","enrollment":245},{"nctId":"NCT07485855","phase":"PHASE3","title":"Influenza Vaccination Strategy for Patients With Hematologic Malignancy","status":"RECRUITING","sponsor":"Asan Medical Center","startDate":"2025-12-04","conditions":"Hematologic Neoplasms, Influenza, Immunogenicity","enrollment":60},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT05227001","phase":"PHASE1","title":"A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-04-28","conditions":"Influenza, Human","enrollment":440},{"nctId":"NCT06489964","phase":"NA","title":"Addressing Unfunded Vaccines Through a Co-payment Mechanism in Pharmacies","status":"RECRUITING","sponsor":"Canadian Immunization Research Network","startDate":"2025-10-23","conditions":"Preventable Disease, Vaccine","enrollment":600},{"nctId":"NCT06087640","phase":"PHASE3","title":"A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seqirus","startDate":"2023-10-23","conditions":"Influenza, Human","enrollment":35800},{"nctId":"NCT05397223","phase":"PHASE1","title":"A Study of Modified mRNA Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-05-24","conditions":"SARS-CoV-2, Seasonal Influenza, Respiratory Syncytial Virus","enrollment":308},{"nctId":"NCT06229392","phase":"PHASE1","title":"A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer","status":"WITHDRAWN","sponsor":"Rush University Medical Center","startDate":"2026-06-01","conditions":"Breast Cancer, Breast Cancer Triple Negative","enrollment":""},{"nctId":"NCT06431607","phase":"PHASE2","title":"A Study to Find the Dose and Assess the Immune Response and Safety of a Vaccine Against Influenza in Healthy Younger and Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":845},{"nctId":"NCT04697576","phase":"PHASE1","title":"Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma","status":"RECRUITING","sponsor":"Carlo Contreras","startDate":"2021-10-20","conditions":"Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8","enrollment":36},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT05294588","phase":"PHASE2","title":"Efficacy of Immunization With 4C-MenB in Preventing Experimental Urethral Infection With Neisseria Gonorrhoeae","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2022-04-18","conditions":"Gonorrhea Male","enrollment":65},{"nctId":"NCT04164212","phase":"PHASE4","title":"Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2020-09-01","conditions":"Influenza","enrollment":33},{"nctId":"NCT07421037","phase":"PHASE1","title":"Clinical Trial of Quadrivalent Subunit Influenza Vaccine (Adjuvant) in Chinese Population Aged 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2025-11-13","conditions":"Influenza, Influenza Vaccine","enrollment":80},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT05108818","phase":"PHASE4","title":"Characterization of Humoral and Cellular Immune Responses Elicited by Influenza Vaccination in Healthy Adults","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-10-07","conditions":"Influenza, Human","enrollment":700},{"nctId":"NCT07211152","phase":"PHASE3","title":"Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-10-13","conditions":"Influenza","enrollment":150},{"nctId":"NCT07111078","phase":"PHASE1","title":"Quadrivalent Influenza HA Stem Vaccine VRC-FLUMOS0122-00-VP (SteMos1) With and Without ALFQ Adjuvant in Healthy Adults","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-08-27","conditions":"Influenza Prevention, Pandemic Influenza Prevention","enrollment":56},{"nctId":"NCT07357467","phase":"","title":"Effect of Oral Supplement on Influenza Vaccine Long-term Response","status":"NOT_YET_RECRUITING","sponsor":"Tsinghua University","startDate":"2026-03","conditions":"Influenza, Immunosenescence","enrollment":30},{"nctId":"NCT04613206","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2021-01-11","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":396},{"nctId":"NCT06850051","phase":"PHASE1","title":"A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2025-03-19","conditions":"Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination","enrollment":270},{"nctId":"NCT06503900","phase":"PHASE4","title":"Simultaneous mRNA COVID-19 and IIV Vaccination in Pregnancy Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2024-09-12","conditions":"Birth Outcomes, Safety, Adverse Event Following Immunization","enrollment":98},{"nctId":"NCT06024096","phase":"PHASE4","title":"Systems Biological Assessment of Statin Effect on Vaccine Responses","status":"COMPLETED","sponsor":"Emory University","startDate":"2023-09-20","conditions":"Vaccine Response","enrollment":63},{"nctId":"NCT07332689","phase":"","title":"Safety Study of Quadrivalent Subunit Influenza Vaccine in People Aged 3 Years and Older","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-10-30","conditions":"Influenza Vaccine","enrollment":42881},{"nctId":"NCT06436703","phase":"PHASE2","title":"A Study About Modified RNA Vaccines Against Influenza in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-23","conditions":"Influenza, Human","enrollment":1202},{"nctId":"NCT05645900","phase":"PHASE3","title":"A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Ab&B Bio-tech Co., Ltd.JS","startDate":"2023-02-06","conditions":"Influenza","enrollment":2772},{"nctId":"NCT05330975","phase":"PHASE3","title":"A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-04-01","conditions":"Respiratory Syncytial Virus","enrollment":3317},{"nctId":"NCT04544267","phase":"PHASE3","title":"Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-15","conditions":"Influenza","enrollment":100},{"nctId":"NCT05827926","phase":"PHASE1, PHASE2","title":"A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-14","conditions":"SARS-CoV-2, Influenza","enrollment":1758},{"nctId":"NCT06694025","phase":"","title":"Post-marketing Surveillance Study for the Safety of Efluelda Tetra Pre-filled Syringe.","status":"NOT_YET_RECRUITING","sponsor":"Sanofi","startDate":"2026-10-01","conditions":"Immunization, Influenza (Healthy Volunteers)","enrollment":670},{"nctId":"NCT06279871","phase":"PHASE3","title":"Immunogenicity and Safety Study of Self-amplifying mRNA COVID-19 Vaccine Administered With Influenza Vaccines in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-03-27","conditions":"COVID-19","enrollment":1514},{"nctId":"NCT05215327","phase":"PHASE2","title":"High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients","status":"RECRUITING","sponsor":"Vanderbilt University Medical Center","startDate":"2022-11-08","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":270},{"nctId":"NCT06831786","phase":"EARLY_PHASE1","title":"Immunogenicity of COVID-19 Vaccine Co-administration With Influenza Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Prince of Songkla University","startDate":"2024-03-01","conditions":"COVID - 19","enrollment":36},{"nctId":"NCT05606965","phase":"PHASE2","title":"A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-11-02","conditions":"Influenza","enrollment":172},{"nctId":"NCT03598439","phase":"PHASE4","title":"Randomized Influenza Vaccine Evaluation of Immune Response","status":"COMPLETED","sponsor":"Marshfield Clinic Research Foundation","startDate":"2018-07-30","conditions":"Influenza","enrollment":366},{"nctId":"NCT06824519","phase":"PHASE1, PHASE2","title":"Clinical Trials of Quadrivalent Influenza Vaccine","status":"RECRUITING","sponsor":"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.","startDate":"2025-05-08","conditions":"Influenza, Human","enrollment":620},{"nctId":"NCT05479370","phase":"PHASE3","title":"Immunogenicity Trial of 3 Influenza Vaccines","status":"COMPLETED","sponsor":"Tan Tock Seng Hospital","startDate":"2022-09-29","conditions":"Influenza Vaccination","enrollment":366},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT03945825","phase":"PHASE1","title":"Flublok or Fluzone With Advax-CpG55.2 or AF03","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-06-10","conditions":"Influenza, Influenza Immunisation","enrollment":241},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT04537234","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-11-10","conditions":"Influenza (Healthy Volunteers)","enrollment":165},{"nctId":"NCT04498832","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-10-21","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":2100},{"nctId":"NCT05779020","phase":"PHASE3","title":"Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2023-04-25","conditions":"Influenza, Human","enrollment":1373},{"nctId":"NCT04137887","phase":"PHASE3","title":"Study to Evaluate the Effectiveness of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Adults 65 Years of Age and Older","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-04","conditions":"Influenza (Healthy Volunteers)","enrollment":33096},{"nctId":"NCT04451954","phase":"PHASE1","title":"Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-07-02","conditions":"Influenza Immunisation, Healthy Volunteers","enrollment":210},{"nctId":"NCT04210349","phase":"PHASE3","title":"Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-01-09","conditions":"Influenza","enrollment":7106},{"nctId":"NCT05426174","phase":"PHASE1","title":"Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-06-09","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":233},{"nctId":"NCT06095947","phase":"","title":"Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years","status":"COMPLETED","sponsor":"Hualan Biological Bacterin Co. Ltd.","startDate":"2021-09-15","conditions":"GCP","enrollment":652},{"nctId":"NCT05517174","phase":"PHASE4","title":"A Pragmatic Randomized Trial to Evaluate the Effectiveness of High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in Older Adults","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2022-09-22","conditions":"Influenza","enrollment":332438},{"nctId":"NCT05829356","phase":"PHASE1","title":"Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-04-12","conditions":"Influenza Immunization","enrollment":159},{"nctId":"NCT04551677","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-09-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT04109222","phase":"PHASE4","title":"Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-09-30","conditions":"Influenza","enrollment":90},{"nctId":"NCT05050318","phase":"PHASE4","title":"Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-09-08","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":90},{"nctId":"NCT06506812","phase":"PHASE4","title":"Pooled Analysis of Methodologically Harmonized Pragmatic Randomized Trials of High-Dose vs. Standard-Dose Influenza Vaccine Against Severe Clinical Outcomes","status":"COMPLETED","sponsor":"Tor Biering-Sørensen","startDate":"2025-05-31","conditions":"Influenza","enrollment":466320},{"nctId":"NCT04969276","phase":"PHASE2","title":"Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-07-16","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":306},{"nctId":"NCT04024228","phase":"PHASE3","title":"Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-10-28","conditions":"Influenza Immunization, Healthy Volunteers","enrollment":1539},{"nctId":"NCT05144945","phase":"PHASE3","title":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-12-07","conditions":"Influenza (Healthy Volunteers)","enrollment":301},{"nctId":"NCT06907667","phase":"NA","title":"Study of the Impact of Time of Vaccination on Response to Influenza Vaccine in Patients With Chronic Renal Failure","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2025-09-03","conditions":"Vaccination; Infection","enrollment":735},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT05513053","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-10-27","conditions":"Influenza Immunization","enrollment":1308},{"nctId":"NCT05513391","phase":"PHASE3","title":"Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-10","conditions":"Influenza Immunization","enrollment":366},{"nctId":"NCT03315975","phase":"PHASE4","title":"Flu Vaccine Responses in the Setting of Melanoma Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Viral Vaccines","enrollment":40},{"nctId":"NCT03346772","phase":"PHASE4","title":"Study of Immune Responses to Influenza Vaccination","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2017-10-20","conditions":"Influenza Vaccination","enrollment":75},{"nctId":"NCT06049927","phase":"PHASE3","title":"A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-09-16","conditions":"Seasonal Influenza","enrollment":3300},{"nctId":"NCT06141655","phase":"PHASE4","title":"HD vs SD Quadrivalent Influenza Vaccine in Adults Aged 65 to 79 Years in Galicia","status":"COMPLETED","sponsor":"Federico Martinón Torres","startDate":"2023-10-26","conditions":"Influenza","enrollment":134476},{"nctId":"NCT06060457","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-09-25","conditions":"Respiratory Syncytial Virus","enrollment":1900},{"nctId":"NCT04144179","phase":"PHASE1","title":"Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-11-06","conditions":"Influenza","enrollment":150},{"nctId":"NCT02783170","phase":"PHASE4","title":"Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-09","conditions":"Pregnancy","enrollment":81},{"nctId":"NCT05663463","phase":"NA","title":"Seasonal Influenza Vaccine High Dose Boosting in Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2023-09-11","conditions":"Solid Organ Transplant","enrollment":74},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT05801978","phase":"PHASE4","title":"Durability of Vaccine Responses","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-04-11","conditions":"Vaccine Response","enrollment":66},{"nctId":"NCT06097273","phase":"PHASE3","title":"A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-10-19","conditions":"SARS-CoV-2, Influenza","enrollment":8061},{"nctId":"NCT06361875","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-04-01","conditions":"Influenza Immunization","enrollment":910},{"nctId":"NCT06067555","phase":"EARLY_PHASE1","title":"Intradermal Influenza Vaccination","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-01-24","conditions":"Vaccine Reaction","enrollment":249},{"nctId":"NCT06020118","phase":"PHASE4","title":"Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-09-25","conditions":"Influenza, COVID-19","enrollment":455},{"nctId":"NCT05291676","phase":"PHASE2","title":"Systems Investigation of Vaccine Responses in Aging and Frailty","status":"RECRUITING","sponsor":"Yale University","startDate":"2023-11-06","conditions":"Influenza","enrollment":96},{"nctId":"NCT06744205","phase":"PHASE1, PHASE2","title":"A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-01-06","conditions":"Influenza, Healthy Volunteers","enrollment":1162},{"nctId":"NCT04487041","phase":"PHASE4","title":"Tfh Dysfunction in HIV and Aging","status":"RECRUITING","sponsor":"University of Miami","startDate":"2020-10-30","conditions":"Human Influenza","enrollment":400},{"nctId":"NCT06054269","phase":"PHASE3","title":"Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-11-04","conditions":"Influenza","enrollment":192},{"nctId":"NCT05071313","phase":"PHASE3","title":"A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-10-04","conditions":"Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention","enrollment":777},{"nctId":"NCT05091307","phase":"PHASE3","title":"A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2021-11-02","conditions":"COVID-19 Prevention","enrollment":861},{"nctId":"NCT05585983","phase":"PHASE4","title":"INfluenza VaccInation To Mitigate typE 1 Diabetes","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2022-12-14","conditions":"Diabetes Mellitus, Type 1","enrollment":100},{"nctId":"NCT05540522","phase":"PHASE3","title":"A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-12","conditions":"Influenza, Human","enrollment":45789},{"nctId":"NCT06015282","phase":"PHASE3","title":"The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Seqirus","startDate":"2023-11-03","conditions":"Influenza, Human","enrollment":7741},{"nctId":"NCT06134804","phase":"PHASE3","title":"A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-10-24","conditions":"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention","enrollment":959},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT04961541","phase":"PHASE1, PHASE2","title":"Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine","status":"COMPLETED","sponsor":"Novavax","startDate":"2021-09-08","conditions":"SARS-CoV Infection, Covid19","enrollment":637},{"nctId":"NCT03694392","phase":"","title":"Flublok v. Standard Dose Vaccine Effectiveness Among Kaiser Permanente Northern California Adults 18-64 Years","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2018-09-16","conditions":"Influenza, Pneumonia, Lower Respiratory Tract Infection","enrollment":2776278},{"nctId":"NCT05648357","phase":"PHASE4","title":"A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-12-14","conditions":"Influenza, Human","enrollment":250},{"nctId":"NCT06738082","phase":"","title":"Influenza Vaccine Elicited Immune Response in Immunocompromised Patients","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-10-15","conditions":"Influenza Vaccine, Immunocompromised Patients","enrollment":147},{"nctId":"NCT05514002","phase":"PHASE4","title":"Comparison of Recombinant Influenza Vaccine Versus Standard Egg-Based Inactivated Influenza Vaccine in Adults 18-64 Years","status":"TERMINATED","sponsor":"Fatimah Dawood","startDate":"2022-09-13","conditions":"Influenza, Human","enrollment":3988},{"nctId":"NCT06059456","phase":"","title":"Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24","status":"COMPLETED","sponsor":"Sanofi","startDate":"2023-10-02","conditions":"Influenza Immunization (Healthy Volunteers)","enrollment":2078},{"nctId":"NCT05947071","phase":"PHASE2","title":"High vs.Standard Dose Influenza Vaccine in Pediatric Solid Organ Transplant (SOT) Recipients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2024-09-26","conditions":"Immunization; Infection, Transplantation Infection, Influenza","enrollment":312},{"nctId":"NCT05650554","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-12-12","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT05624606","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2022-11-28","conditions":"Influenza Immunization","enrollment":682},{"nctId":"NCT01997450","phase":"","title":"A Case Control Study of the Effectiveness of Q/LAIV Versus Inactivated Influenza Vaccine and No Vaccine in Subjects 2-17 Years of Age","status":"TERMINATED","sponsor":"MedImmune LLC","startDate":"2013-12-02","conditions":"Influenza Vaccine Effectiveness","enrollment":4121},{"nctId":"NCT03898986","phase":"PHASE1","title":"The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets","status":"COMPLETED","sponsor":"Stanford University","startDate":"2019-10-08","conditions":"Influenza","enrollment":18},{"nctId":"NCT03932682","phase":"PHASE3","title":"Efficacy Study With QIVc in Pediatric Subjects","status":"COMPLETED","sponsor":"Seqirus","startDate":"2019-05-13","conditions":"Influenza, Human","enrollment":5723}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Flucelvax Quadrivalent vaccine","genericName":"Flucelvax Quadrivalent vaccine","companyName":"Tan Tock Seng Hospital","companyId":"tan-tock-seng-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"Flucelvax Quadrivalent is an inactivated influenza vaccine produced using cell culture technology that stimulates immune response against four strains of influenza virus. Used for Seasonal influenza prevention in adults and children.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}